Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
| Revenue (TTM) | $1.22B |
| Gross Profit (TTM) | $804.88M |
| EBITDA | $355.05M |
| Operating Margin | 23.40% |
| Return on Equity | 9.03% |
| Return on Assets | 6.26% |
| Revenue/Share (TTM) | $7.79 |
| Book Value | $13.32 |
| Price-to-Book | 5.35 |
| Price-to-Sales (TTM) | 9.28 |
| EV/Revenue | 9.31 |
| EV/EBITDA | 32.37 |
| Quarterly Earnings Growth (YoY) | 128.60% |
| Quarterly Revenue Growth (YoY) | 1.30% |
| Shares Outstanding | $155.81M |
| Float | $155.47M |
| % Insiders | 0.32% |
| % Institutions | 115.60% |
Volatility is currently contracting
Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.
MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026.
Techne (TECH) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.53 per share a year ago.
Bio-Techne beat Wall Street estimates for fourth-quarter revenue on Wednesday helped by growth in its research and diagnostics businesses.
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter FY2026 Highlights Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million.
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters. The bottom five detractors for the quarter were Ross Stores, Arch Capital, Copart, Gartner, and Brown & Brown. We purchased shares in Verisk Analytics, the dominant provider of data and analytics to property and casualty insurers in the U.S.
TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.
Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing MINNEAPOLIS, July 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TECH and any ticker you trade — then tracks every position and per-strategy win rate.
